Meeting Banner
Abstract #1304

Vertebral bone marrow fat content changes in postmenopausal women receiving combined aromatase inhibitor and bisphosphonate therapy after one year

Michael Dieckmeyer1,2, Stefan Ruschke2, Alexander Rohrmeier2, Jan Syväri2, Ingo Einspieler2, Jan S. Kirschke1, Ernst J. Rummeny2, Claus Zimmer1, Dimitrios C. Karampinos2, and Thomas Baum1

1Department of Diagnostic and Interventional Neuroradiology, Technical University of Munich, München, Germany, 2Department of Diagnostic and Interventional Radiology, Technical University of Munich, München, Germany

In recent years in-vivo assessment of vertebral bone marrow (VBM) fat composition has been increasingly used in the investigation of osteoporosis and bone metabolism. Postmenopausal women represent a population of particular interest because they are at higher risk for osteoporosis resulting from estrogen deficiency which can be potentially aggravated by aromatase inhibitor (AI) therapy. The present study demonstrated a relative increase in vertebral bone marrow fat content quantified by chemical shift encoding-based water-fat MRI in patients receiving simultaneous AI and bisphosphonate (BP) therapy, contradicting previous findings reported in the literature.

This abstract and the presentation materials are available to members only; a login is required.

Join Here